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Background: In adult population with community acquired pneumonia high levels of pro-adrenomedullin
(pro-ADM) have been shown to be predictors of worse prognosis. The role of this biomarker in pediatric patients
had not been analyzed to date. The objective of this study is to know the levels of pro-ADM in children with
community acquired pneumonia (CAP) and analyze the relation between these levels and the patients’ prognosis.
Findings: Prospective observational study including patients attended in the emergency service (January to
October 2009) admitted to hospital with CAP and no complications at admission. The values for pro-ADM were
analyzed in relation to: need for oxygen therapy, duration of oxygen therapy, fever and antibiotic therapy,
complications, admission to the intensive care unit, and length of hospital stay. Fifty patients were included.
Ten presented complications (7 pleural effusion). The median level of pro-ADM was 1.0065 nmol/L
(range 0.3715 to 7.2840 nmol/L). The patients presenting complications had higher levels of pro-ADM
(2.3190 vs. 1.1758 nmol/L, p = 0.013). Specifically, the presence of pleural effusion was associated with higher levels
of pro-ADM (2.9440 vs. 1.1373 nmol/L, p< 0.001).
Conclusions: In our sample of patients admitted to hospital with CAP, pro-ADM levels are related to the
development of complications during hospitalization.
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Background
In recent years several clinical and analytical scales have
been developed to evaluate severity and prognosis of
adult patients with community-acquired pneumonia
(CAP), such as Pneumonia Severity Index (PSI) [1],
CURB-65 and CRB-65 [2]. Furthermore, many studies
have examined the usefulness of diverse biomarkers in
the diagnostic, etiological, and prognostic classification
of these patients [3-5]. One of the biomarkers evaluated* Correspondence: gclaret@hsjdbcn.org
1Emergency Department, Hospital Sant Joan de Déu, Universitat de
Barcelona, Passeig Sant Joan de Déu 2, 08950 Esplugues de Llobregat,
Barcelona, Spain
Full list of author information is available at the end of the article
© 2012 Sardà Sánchez et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumis pro-adrenomedullin (pro-ADM) [6,7]. This is a pep-
tide originally isolated in human pheochromocytoma in
1993 with a powerful vasodilating and bactericide effect.
High levels of pro-ADM have been shown to be predic-
tors of seriousness and mortality in various pathologies
in adult population [6-9]. Specifically, in CAP, two recent
studies have shown that patients with high levels of pro-
ADM present a worse prognosis [6,7]. The role of pro-
ADM in a pediatric population had not been analyzed to
date.
Objectives of our study were to determine the levels of
pro-ADM in pediatric patients suffering CAP, and to
analyze the relation between these levels and the
patients’ prognosis.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The study was carried out in a tertiary-care children’s
hospital with 275 beds and an average referral popula-
tion of 1,200,000 children under the age of 18 years, and
105,485 patients attended in the Emergency Service (ES)
every year.
This is a prospective observational study including
patients under 18 years of age attended between January
and October 2009 in the ES and hospitalized with CAP
as the main diagnosis, and blood work carried out at ad-
mission. CAP was defined as acute pulmonary inflam-
mation involving the aerial and interstitial space of
infectious origin, according to the classical combination
of clinical and radiological findings (code 486 in the
diagnosis coding of the Spanish Emergency Pediatrics
Society). Chest radiographs were screened by the phys-
ician in charge and reviewed by a senior radiologist.
Patients were excluded if they had an immunocompro-
mising or chronical medical condition predisposing
them to severe pneumonia (chronic cardiopulmonary
disease, primary or acquired immunodeficiency, neuro-
muscular disease or cerebral palsy). Those patients with
complicated CAP at the time of admission and those re-
ceiving oral or parenteral antibiotic treatment for a pre-
vious diagnosis of CAP were also excluded.
For the purposes of the present study we considered
complicated CAP when one of the following was
present: pleural effusion, cavitation, lung abscess or ne-
crosis, air escape, massive atelectasis or signs of systemic
infection (sepsis).
Admission criteria in our center for patients with CAP
are age under three months, age under one year with
moderate-to-severe symptoms, any age with severe clin-
ical state, underlying illness susceptible to decompensa-
tion, involvement of more than one lobe or extensive
unilobar involvement, pleural effusion, cavitary pneumo-
nia or lung abscess, pneumonia that failed to respond to
correct antibiotic treatment begun in the previous 48–
72 hours, oral intolerance or suspected therapeutic non-
compliance. The physician in charge decides on the need
for blood work or for initiating endovenous antibiotic
treatment. When blood work was carried out, determin-
ation of pro-ADM levels were also performed. Pro-ADM
levels were known after the discharge of the patients.
To know whether pro-ADM levels were correlated
with prognosis, its levels were measured in relation to
the following parameters: need for oxygen therapy, dur-
ation of fever, oxygen and parenteral antibiotic therapy
during hospitalization, length of hospital stay, admission
to Intensive Care Unit (ICU), and development of com-
plications. In our hospital oxygen therapy is indicated
when percutaneous oxygen saturation is under 95% or
when significant respiratory distress is present. In
addition, pro-ADM levels were also compared accordingto the site of pneumonia (unilobar versus multilobar) at
admission.
The study was approved by the Local Human Investi-
gation Ethics Committee. Verbal informed consent was
obtained from all parents or legal tutors of the patients
before inclusion in the study.
Processing of the sample
EDTA was added to the blood sample in order to meas-
ure pro-ADM. For its measurement in blood serum,
TRACE (time-resolved amplified cryptase emission)
technology was used by Kryptor Compact pro-ADM W
(Brahms, Hennigsdorf, Germany). This system has an
optimized functional sensitivity (inter-assay precision:
20%) of 0.25 nmol/L.
Statistical analysis
Data analysis was conducted using SPSS 17.0 software.
The study population was described using frequencies
and percentages for categorical variables and means,
standard deviations, medians, ranges and interquartile
ranges (IQR) for continuous variables. Statistical com-
parisons were made using a chi-square test or Fisher
exact test for categorical data, and a student’s t-test or
Mann–Whitney U test for continuous data. Dependence
between continuous variables was determined with Pear-
son’s correlation. P values less than 0.05 were considered
significant.
Results and discussion
During the study period 2066 patients were diagnosed
with CAP in the ES. A total of 298 were admitted to
hospital (14.4%); 187 of them were excluded for present-
ing any of the mentioned exclusion criteria. Of the 111
remaining patients, 61 were excluded because there was
not blood work done at admission (19 cases) or because
there was no pro-ADM in the blood sample taken at ad-
mission (42 cases). The final sample was composed of 50
patients. There were no statistically significant differ-
ences between the clinical characteristics of these last
two groups at the evaluation in the ES (Table 1).
Of the 50 patients included in the study, 18 had
received at least 2 doses heptavalent pneumococcal con-
jugate vaccine. Thirty (60%) received oxygen therapy
during admission, with a median duration of two days
(range 0.5 to 11). A total of 42 patients presented fever
during admission (84%), with a median duration of one
day (range 0.5 to 10). All patients received antibiotics for
a median time of 4 days (range 2 to 24). During the hos-
pital stay 10 patients (20%) presented complications:
pleural effusion (7 cases), pulmonary abscess (two cases),
and massive atelectasis (one case). Six patients with
pleural effusion required pleural drainage, in two cases
with prior thoracoscopy. Five children (10%) required
Figure 1 Pro-adrenomedullin levels in the 50 patients
according to the development of complications during
admission.
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and two with mechanical ventilation. All 5 patients pre-
sented a good evolution. Median length of stay was
5 days (range 2 to 25).
The median level of pro-ADM was 1.0065 nmol/L
(range 0.3715 to 7.2840, IQR 0.7598 to 1.3588). The
patients with complicated pneumonia had higher levels
of pro-ADM than those who did not develop complica-
tions (2.3190 vs. 1.1758 nmol/L, p = 0.013), as we show
in Figure 1. Concretely, the patients with pleural effusion
had a median level of pro-ADM of 2.9440 vs.
1.1373 nmol/L for the patients not presenting this com-
plication (p< 0.001). C-reactive protein (CRP) levels not
differ between patients with uncomplicated and uncom-
plicated CAP (206 vs. 254.5 mg/L, p = 0.558). No statisti-
cally significant relation was found between pro-ADM
levels and the other variables analyzed: need for oxygen
therapy (1.5 vs. 1.3, p = 0.8), duration of fever during
hospital stay (Pearson correlation index 0.2; p = 0.2), dur-
ation of oxygen therapy (Pearson correlation index 0.01;
p = 0.9), length of hospital stay (Pearson correlation
index 0.2; p = 0.2), duration of parenteral antibiotic ther-
apy (Pearson correlation index 0.2; p = 0.1), admission to
ICU (1.4 vs. 0.9, p = 0.5) and unilobar or multilobar CAP
at admission (1.1 vs. 0.9, p = 0.585).
To our knowledge this is the first study that evaluates
the levels of pro-ADM in pediatric patients with CAP.
Our purpose was analyzing the usefulness of this param-
eter as a predictor of patient evolution.
Two main mechanisms have been described as respon-
sible for the increase of circulating pro-ADM in infec-
tions, including CAP, which can be regarded as a
precursor of sepsis. Firstly, as a member of the calcitonin
gene family, ADM is widely expressed and extensively
synthesized during severe infections. Bacterial endotox-
ins and proinflammatory cytokines up-regulate ADM
gene expression in many tissues. In addition, a decreasedTable 1 Clinical characteristics at admission of the 50 patient
because of the lack of pro-ADM levels
Included patients (n
Female sex, n (%) 26 (52
Age 4.5 years (1.9 month
Maximum temperature, °C 39.5 (38–4
Duration of fever, days 3 (0.2 to
Respiratory distress, n (%) 26 (52
Percutaneous oxygen saturation< 95%, n (%) 16 (32
Chest radiograph
- Unilobar infiltrate, n (%) 36 (72
- Multilobar infiltrate, n (%) 10 (20
- Interstitial infiltrate, n (%) 4 (8)
The values are displayed as medians and ranges, unless otherwise indicated.clearance by the kidneys may be responsible in part for
the increased pro-ADM levels in infections [10].
The median level of pro-ADM found in our study was
similar to those found by Christ-Crain et al. [6] and
Huang DT et al. [7] in adult population with CAP:
1.1 nmol/L (IQR 0.7-1.9) and 1.0 nmol/L (IQR 0.7-1.5)
respectively.
In our study higher levels of pro-ADM at the time of
diagnosis correlated with further development of compli-
cations during hospital stay, especially pleural effusion.
However, there was an overlapping of pro-ADM’s levels
between the patients presenting complications and the
rest. This issue could be probably addressed in a larger
study. None of the published studies evaluating pro-
ADM levels in adult population with CAP analyzed
specifically the relation between pro-ADM levels and
development of pleural effusion during admission.
Christ-Crain et al. [6] included 302 patients and observeds included in the study and the 61 patients excluded
=50) Excluded patients (n = 61) p
) 28 (45.9) 0.327
s to 13.6 years) 2.5 years (23 days to 12.9 years) 0.74
0.7) 39 (37–41.2) 0.41
7) 3 (0–21) 0.838
) 42 (68.8) 0.053
) 25 (40.9) 0.159
) 39 (63.9) 0.512
) 13 (21.3)
9 (14.7)
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of illness according to the PSI score and death. They pro-
posed a cut-off point of 1.8 nmol/L (80% sensitivity, 72%
specificity). A later multicenter study by Huang DT et al.
[7] including 1653 patients found higher levels of pro-
ADM in patients stratified into higher risk groups
according to the PSI and the CURB-65 scores. They also
found that higher levels of pro-ADM at admission were
associated with an increased need for intensive care,
vasopressors, and increased mortality. The cut-off pro-
posed by the authors was 1.3 nmol/L (68% sensitivity,
73% specificity). Recently, Albrich et al. [11] in a multi-
center study including 1359 adult patients with lower re-
spiratory tract infection proposed a new score combining
CURB65 risk classes with pro-ADM levels to predict ad-
verse events and mortality. In other recent study, Bello
et al. [12] confirmed pro-ADM high short- and long-
term prognostic accuracy, and that this biomarker
increased the accuracy of clinical scores. In the men-
tioned manuscripts the prognostic value of MR-proADM
was not modified by different possible CAP aetiologies.
In our study we could not address this issue due to lack
of information about CAP aetiology. Suberviola et al.
[13] included 49 patients with severe sepsis or septic
shock due to CAP. Pro-ADM levels correlated with death
and increasing severity of illness, levels rose as PSI class
advanced.
The present study has several limitations: 1) Patients
discharged were not included because, according to our
protocol, these patients usually don’t need blood work;
for that reason pro-ADM levels obtained are not repre-
sentative of general pediatric population with CAP; 2)
Strict exclusion criteria were applied in order to insure a
homogeneous sample; again, results obtained can’t be
applied to all pediatric patients hospitalized with CAP;
3) Furthermore we excluded a relevant number of
patients in whom pro-ADM determination was not
obtained. This fact could have introduced a bias into the
pro-ADM values obtained, because patients without
blood sample had probably a mildness disease. Never-
theless, comparison between two groups showed no sta-
tistically significant differences in clinical characteristics
at admission. In addition, values obtained in our sample
were similar to those obtained in the studies of CAP in
adults that included patients admitted to hospital and
those discharged [6,7]. As a consequence of these limita-
tions, the final sample size was small and we were not
able to establish prognosis cut-off values or to analyze
subgroups of patients.
Conclusions
In conclusion, in our sample a higher level of pro-ADM
at admission was related to a greater likelihood of com-
plications during the hospital stay and therefore it couldbe helpful in the management of patients with CAP in
the ES. Nevertheless, future studies with larger samples
will be needed to confirm our results and to analyze the
association of pro-ADM levels with other variables of
prognostic significance.
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